Pangaea Oncology (XMAD:PANG) Total Equity: €22.06 Mil (As of Dec. 2025)


XMAD:PANG Pangaea Oncology SA XMAD:PANG
63 GF Score
Price €1.51
GF Value €2.16
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Pangaea Oncology Total Equity?

Pangaea Oncology XMAD:PANG 63 Total Equity is €22.06 Mil as of Dec. 2025. GuruFocus rates XMAD:PANG with a GF Score™ of 63/100 and a GF Value™ of €2.16 (Possible Value Trap). The stock has 7 warning signs investors should review.

Pangaea Oncology's total equity for the quarter that ended in Dec. 2025 was €22.06 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Pangaea Oncology Total Equity Historical Data

* Premium members only.

The historical data trend for Pangaea Oncology's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pangaea Oncology Total Equity Chart

Pangaea Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.09 23.08 18.71 22.84 22.06

Pangaea Oncology Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.71 16.92 22.84 21.14 22.06
XMAD:PANG
63GF Score
Pangaea Oncology SA XMAD:PANG
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pangaea Oncology Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Pangaea Oncology's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=32.109-10.049
=22.06

Pangaea Oncology's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=32.109-10.049
=22.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €22.06 Mil mean?
Pangaea Oncology (XMAD:PANG) has a Total Equity of €22.06 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Pangaea Oncology and its competitors.
Is Pangaea Oncology's Total Equity too high?
Pangaea Oncology's current Total Equity is €22.06 Mil. Overall, Pangaea Oncology has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pangaea Oncology's Total Equity compare to TMO and DHR?
Pangaea Oncology's Total Equity of €22.06 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Diagnostics & Research company?
A good Total Equity depends on the Medical Diagnostics & Research industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Pangaea Oncology and its competitors. Pangaea Oncology's current Total Equity is €22.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pangaea Oncology stock overvalued right now?
Based on GuruFocus' analysis, Pangaea Oncology (XMAD:PANG) is currently considered Possible Value Trap. The stock's GF Value™ is €2.16, compared to a current price of €1.51 — trading 30.1% below its estimated fair value. The current Total Equity is €22.06 Mil. Pangaea Oncology's overall GF Score™ is 63/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Pangaea Oncology (XMAD:PANG), the current Total Equity is €22.06 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pangaea Oncology (XMAD:PANG) Overvalued in 2026?

Based on GuruFocus' analysis, Pangaea Oncology stock appears to be undervalued. The current stock price of €1.51 is trading 30.1% below its estimated GF Value™ of €2.16. GuruFocus considers Pangaea Oncology to be Possible Value Trap.

Key valuation signals for XMAD:PANG:

  • Total Equity: €22.06 Mil
  • GF Value™: €2.16 vs. price of €1.51 (30.1% below fair value)
  • GF Score™: 63/100 with 7 warning signs

No single metric tells the full story. See the XMAD:PANG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pangaea Oncology Business Description

Address Calle Sabino Arana, 5-19, Barcelona, ESP, 08028
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
63GF Score

Get the complete analysis for XMAD:PANG

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.51
Price
€2.16
GF Value